Overview

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory AML

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, pharmacokinetic of APG-2575 single agent and in combination with HHT/AZA in patients with relapsed/refractory AML.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ascentage Pharma Group Inc.

Collaborators:

Suzhou Yasheng Pharmaceutical Co., Ltd
Suzhou Yasheng Pharmaceutical Co., Ltd.

Treatments:

Azacitidine